Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab

Future Oncology

Volumn 9, Issue 8, 2013, Pages 1207-1214

  Scartozzi, Mario ^a   Giampieri, Riccardo ^a   Loretelli, Cristian ^a   Mandolesi, Alessandra ^a   Prete, Michela Del ^a   Biagetti, Simona ^a   Alfonsi, Simona ^a   Faloppi, Luca ^a   Bianconi, Maristella ^a   Bittoni, Alessandro ^a   Bearzi, Italo ^a   Cascinu, Stefano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

cetuximab; colorectal tumors; EGFR; HER 3; integrins

Indexed keywords

ALPHA6 INTEGRIN; BETA4 INTEGRIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 3; IRINOTECAN; K RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; FEMALE; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; GENOTYPE; HUMANS; INTEGRIN ALPHA6; INTEGRIN BETA4; ONCOGENE PROTEIN P21(RAS); POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3;

EID: 84881304738     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.72     Document Type: Article

References (21)

1. van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408-1417 (2009).
2. Lievre A, Bachet JB, Boige V et al. Kras mutation as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 28, 374-379 (2008).
3. Di Fiore F, Blanchard F, Charbonnier F et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br. J. Cancer 96, 1166-1169 (2007).
4. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al. Oncogenetic activation of RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 67, 2643-2648 (2007).
5. Kohne C, Rougier P, Stroh C et al. Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): A meta-analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. Presented at: Gastrointestinal Cancers Symposium. Orlando, FL, USA, 22-24 January 2010 (Abstract 406).
6. Scartozzi M, Mandolesi A, Giampieri R et al. The role of HER 3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. Oncologist 16, 53-60 (2011).
7. Scartozzi M, Giampieri R, Maçi E et al. Analysis of HER 3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. Ann. Oncol. 23, 1706-1712 (2012).
8. Berlin J, Keedy VL, Janne PA et al. A first-in-human Phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in patients (pts) with advanced solid tumors. J. Clin. Oncol. 29 (Suppl.), Abstract 3026 (2011).
9. Elez E, Kocáková I, Hoehler T et al. Phase I study of EMD 525797 (DI17E6), an antibody targeting anb integrins, in combination with cetuximab and irinotecan, as a second-line treatment for patients with k-ras wild-type metastatic colorectal cancer. J. Clin. Oncol. 30 (Suppl.), Abstract 3539 (2012).
10. Hood J, Cheresh D. Role of integrins in cell invasion and migration. Nat. Rev. 2, 91-103 (2002).
11. Hynes RO. Integrins. Versatility, modulation and signaling in cell adhesion. Cell 69, 11-25 (1992).
12. Jin H, Varner J. Integrins: Roles in cancer development and as treatment targets. Br. J. Cancer 90, 561-565 (2004).
13. Scartozzi M, Loretelli C, Bearzi I et al. Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. Ann. Oncol. 22, 897-902 (2011).
14. Folgiero V, Avetrani P, Bon G et al. Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas. PLoS ONE 13, e1592 (2008).
15. Bon G, Folgiero V, Di Carlo S, Sacchi A, Falcioni R. Involvement of alpha6beta4 integrin in the mechanisms that regulate breast cancer progression. Breast Cancer Res. 9, 203-207 (2007).
16. Folgiero V, Bachelder RE, Bon G, Sacchi A, Falcioni R, Mercurio AM. The alpha6beta4 integrin can regulate ErbB-3 expression: Implications for alpha6beta4signaling and function. Cancer Res. 67, 1645-1652 (2007).
17. Bon G, Di Carlo SE, Folgiero V et al. Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 mpairs tumor progression. Cancer Res. 69, 5978-5986 (2009).
18. Bon G, Folgiero V, Bossi G et al. Loss of beta4 integrin subunit reduces the tumorigenicity of MCF7 mammary cells and causes apoptosis upon hormone deprivation. Clin. Cancer Res. 12, 3280-3287 (2006).
19. Lesniak D, Xu Y, Deschenes J et al. Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. Cancer Res. 69, 8620-8628 (2009).
20. Huang C, Park CC, Hilsenbeck SG et al. b1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res. 13, R84 (2011).
21. Lao VV, Darwanto A, Sowers LC. Impact of base analogs within CpG dinucleotide on the binding of DNA by the methyl-binding domain of MeCP2 and methylation by DNMT. Biochemistry 30, 10228-10236 (2010).